TITLE:
Sorafenib Acts through VEGFR-2 Inhibition in a Metastatic Clear-Cell Sarcoma of the Kidney
AUTHORS:
Tu V. Dao, Thuan V. Tran, Christophe Lebœuf, Morad El-Bouchtaoui, Jérôme Verine, Anne Janin, Guilhem Bousquet
KEYWORDS:
Tyrosine-Kinase Inhibitor, VEGFR2, Metastases, Clear-Cell Sarcoma of the Kidney
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.7 No.7,
July
5,
2016
ABSTRACT: We report here the case of a young patient with metastatic clear-cell
sarcoma of the kidney resistant to standard chemotherapy, and with complete
response under sorafenib treatment. The remarkable response of her tumor to
sorafenib led us to study sorafenib molecular targets in the metastatic tissue.
Background: Biomarkers predicting response to anti-angiogenic tyrosine kinase
inhibitors remain to be identified. Methods and Findings: In this paper, we
studied the molecular targets of sorafenib in the lung metastasis of a kidney
clear-cell sarcoma. In a patient with complete response under sorafenib
treatment, we showed high VEGFR2 expression by tumor endothelial cells from the
lung metastasis. Conclusion: The original mechanistic results that we obtained
using immunostainings and quantitative RT-PCR on laser-microdissected tumor
endothelial cells have a direct application in daily clinical practice:
metastatic tumors with a large angiogenic component should be tested for VEGFRs
expression to consider anti-angiogenic tyrosine kinase inhibitor treatments.